Jilin Aodong Pharmaceutical Group Co., Ltd. specializes in the manufacturing and marketing of pharmaceutical products. Besides, the group offers food products. Net sales break down by activity as follows: - sale of pharmaceutical products (89.4%); - sale of food products (6.8%); - other (3.8%). All sales are in China.

Employees

5,461

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-07-15	CN¥18.66	+4.30%	27,751,556
26-07-14	CN¥17.89	+2.23%	15,633,702
26-07-13	CN¥17.50	-0.79%	12,861,097
26-07-10	CN¥17.64	-1.07%	14,006,300
26-07-09	CN¥17.83	+0.73%	12,360,059

End-of-day quote Shenzhen S.E.

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

End-of-day quote Shenzhen S.E. Other stock markets 2026-07-15			5-day change	1st Jan Change
18.66 ^CNY	+4.30%		+3.32%	-4.45%

06-09	China Approves Aodong Subsidiary's Levocarnitine Injection	MT
05-21	Jilin Aodong Pharmaceutical Gets China Approval for Supplemental Registration of Heart Drug	MT

Market Cap	21.88B 3.23B 2.82B 2.61B 2.4B 4.54B 311B 4.62B 31.11B 12.21B 152B 12.13B 11.87B 524B	P/E 2024	13.1x	P/E 2025	9.57x
Enterprise Value	21.15B 3.12B 2.73B 2.52B 2.32B 4.39B 301B 4.46B 30.08B 11.8B 147B 11.73B 11.48B 506B	EV / Sales 2024	7.76x	EV / Sales 2025	9.49x
Free-Float	67.59%	Yield 2024	2.9%	Yield 2025	2.56%

06-09	China Approves Aodong Subsidiary's Levocarnitine Injection	MT
05-21	Jilin Aodong Pharmaceutical Gets China Approval for Supplemental Registration of Heart Drug	MT
05-12	Jilin Aodong Pharmaceutical Group Co., Ltd. Approves Final Cash Dividend on A Shares for the Year 2025, Payable on 08 July 2026	CI
04-29	Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-20	Jilin Aodong Pharmaceutical's Attributable Profit Jumps 54% in 2025	MT
04-17	Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-12	Aodong Pharmaceutical's Subsidiary Gets Nod to Market 10 Traditional Chinese Medicines	MT
01-26	Beijing Sun-Novo Pharmaceutical Research Co., Ltd. cancelled the acquisition of Jiangsu Langyan Life Technology Holdings Co., Ltd. from Li Qian, Ganzhou Langyi Investment Center (Limited Partnership) and Other shareholders.	CI
25-10-30	Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-10-21	Aodong Pharmaceutical Gets China Supplementary Nod for Anti-Opioid Medication	MT
25-09-22	Jilin Aodong Pharmaceutical Group Co., Ltd. Approves Interim Cash Dividend on A Shares for 2025, Payable on October 22, 2025	CI
25-09-01	Jilin Aodong Pharmaceutical Group Co., Ltd. Proposes Interim Profit Distribution Plan for 2025	CI
25-08-29	Jilin Aodong Yanbian Pharmaceutical Co., Ltd. announced that it expects to receive CNY 134.393064 million in funding from Jilin Aodong Pharmaceutical Group Co., Ltd.	CI

1 day	+4.30%
1 week	+3.32%
Current month	+5.25%
1 month	+7.30%
3 months	+1.80%
6 months	-7.58%
Current year	-4.45%

Jilin Aodong Pharmaceutical Group Co., Ltd. Stock

Stocks

000623

CNE000000719

Pharmaceuticals

Valuation: Jilin Aodong Pharmaceutical Group Co., Ltd.

Chart: Jilin Aodong Pharmaceutical Group Co., Ltd.

Latest news : Jilin Aodong Pharmaceutical Group Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Jilin Aodong Pharmaceutical Group Co., Ltd.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	17.27	18.68
1 month	17.08	18.88
Current year	16.36	20.93
1 year	16.36	22.08
3 years	12.49	22.08
5 years	12.49	22.08
10 years	12.49	29.43

Manager	Title	Age	Since
Shu Qin Guo CEO	Chief Executive Officer	63	2017-07-16
Kai Yang DFI	Director of Finance/CFO	49	2004-04-30
Shu Yuan Zhang DFI	Director of Finance/CFO	54	2007-06-17

Director	Title	Age	Since
Shu Qin Guo BRD	Director/Board Member	63	2000-01-31
Yu Ju Sun BRD	Director/Board Member	54	2008-05-05
Shu Yuan Zhang BRD	Director/Board Member	54	2020-07-16

Date	Insider	Type	Main position	Quantity	% Market Cap.
11-24	An Ning Li	Buy		100	0.0000%
24-07-28	Shu Qin Guo	Buy	Chief Executive Officer	320,000	0.0276%
24-07-28	Xiu Lin Li	Buy	Chairman	350,000	0.0302%

	2024	2025
Net sales	2.61B 386M 337M 311M 286M 542M 37.1B 551M 3.71B 1.46B 18.13B 1.45B 1.42B 62.5B	2.34B 345M 302M 278M 256M 485M 33.19B 493M 3.32B 1.3B 16.22B 1.3B 1.27B 55.91B
Net income	1.55B 229M 200M 185M 170M 322M 22.05B 327M 2.21B 866M 10.78B 861M 842M 37.14B	2.4B 354M 309M 285M 262M 497M 34.04B 505M 3.41B 1.34B 16.64B 1.33B 1.3B 57.35B
Net Debt	-386M -57.01M -49.84M -45.98M -42.26M -80.08M -5.49B -81.45M -549M -215M -2.68B -214M -209M -9.24B	-724M -107M -93.49M -86.24M -79.28M -150M -10.29B -153M -1.03B -404M -5.03B -402M -393M -17.33B

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
JILIN AODONG PHARMACEUTICAL GROUP CO., LTD.	+4.30%	+3.32%	+1.14%	+15.26%	3.1B
ELI LILLY AND COMPANY	+0.35%	-6.39%	+44.70%	+157.34%	1,028B
JOHNSON & JOHNSON	-2.69%	-7.57%	+57.52%	+54.51%	611B
ABBVIE INC.	+0.44%	-4.14%	+27.46%	+79.48%	432B
ROCHE HOLDING AG	+0.98%	-2.74%	+28.13%	+21.76%	323B
NOVARTIS AG	-0.34%	-3.79%	+26.52%	+43.60%	277B
ASTRAZENECA PLC	+1.63%	-12.52%	+17.86%	+21.72%	257B
NOVO NORDISK A/S	+3.39%	+0.95%	-25.43%	-37.83%	217B
AMGEN INC.	+0.86%	-2.66%	+20.63%	+57.55%	192B
GILEAD SCIENCES, INC.	+1.28%	-3.42%	+17.49%	+70.62%	161B
Average	+1.02%	-4.25%	+21.60%	+48.40%	350.14B
Weighted average by Cap.	+0.19%	-5.51%	+32.92%	+76.65%